<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942952</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2019-0491</org_study_id>
    <nct_id>NCT03942952</nct_id>
  </id_info>
  <brief_title>PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.</brief_title>
  <acronym>SONICS</acronym>
  <official_title>PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Central Nervous System (CNS) demyelinating conditions include multiple sclerosis (MS), Acute
      Disseminated Encephalomyelitis (ADEM), Neuromyelitis Optica Spectrum Disorder (NMOSD) and
      Transverse Myelitis (TM). The symptoms of these conditions are quite variable from patient to
      patient, but can include motor, sensory, visual, gait and cognitive changes. Conventional MRI
      can be used to look for new anatomic changes, but fails to measure underlying biochemical
      changes in brain tissue. The purposes of this study are to identify the biologic and anatomic
      correlations between cognitive profiles and disease activity using MRI imaging techniques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric patients (age 12 to 18 inclusive) with a diagnosis of multiple sclerosis, ADEM,
      anti-MOG mediated demyelinating disease as well as healthy controls will be recruited to
      undergo clinical testing. The study visits will include neuropsychological testing, optical
      coherence tomography (OCT) and MRI on both the 3T and 7T magnet. Subjects will be asked to
      undergo two study visits separated by 12 months +/- 2 months. Each study visit will have the
      same neuropsychological, OCT, and research MRI examinations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MRI Brain without contrast</measure>
    <time_frame>10-14 months</time_frame>
    <description>3T MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI Brain without contrast</measure>
    <time_frame>10-14 months</time_frame>
    <description>7T MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Delis-Kaplan Executive Function System (D-KEFS) Color</measure>
    <time_frame>10-14 months</time_frame>
    <description>Executive Functioning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Word Interference Test (CWIT)</measure>
    <time_frame>10-14 months</time_frame>
    <description>Executive Functioning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Symbol Digit Modalities (SDMT)- Oral Version</measure>
    <time_frame>10-14 months</time_frame>
    <description>Processing Speed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Beery-Buktencia Developmental Test of Visual-Motor Integration, Sixth Edition (VMI-6)</measure>
    <time_frame>10-14 months</time_frame>
    <description>Visual-Motor Integration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Wechsler Intelligence Scale for Children-5th edition (WISCV)</measure>
    <time_frame>10-14 months</time_frame>
    <description>Simple Auditory Attention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Wechsler Adult Intelligence Scale-Fourth edition (WAIS-IV) Digits Forward</measure>
    <time_frame>10-14 months</time_frame>
    <description>Simple Auditory Attention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of WISC-V or WAIS-IV Digits Backward</measure>
    <time_frame>10-14 months</time_frame>
    <description>Working Memory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of California Verbal Learning Test- Children's Version (CVLT-C) or California Verbal Learning Test-Second Edition (CVLT-II)</measure>
    <time_frame>10-14 months</time_frame>
    <description>Verbal Learning and Memory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change i Score of D-KEFS Letter and Category Fluency</measure>
    <time_frame>10-14 months</time_frame>
    <description>Verbal Fluency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of WASI-II</measure>
    <time_frame>10-14 months</time_frame>
    <description>Estimate of IQ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Woodcock-Johnson Tests of Achievement Letter Word identification</measure>
    <time_frame>10-14 months</time_frame>
    <description>Basic Reading Skill</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Reading Fluency</measure>
    <time_frame>10-14 months</time_frame>
    <description>Reading Speed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Calculation</measure>
    <time_frame>10-14 months</time_frame>
    <description>Math Calculation Skills</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Math Fluency</measure>
    <time_frame>10-14 months</time_frame>
    <description>Math Speed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Word Attack</measure>
    <time_frame>10-14 months</time_frame>
    <description>Phoneme/Grapheme Knowledge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Grooved Pegboard</measure>
    <time_frame>10-14 months</time_frame>
    <description>Bilateral Fine Motor Speed and Dexterity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Trail Making Test, Part A and B</measure>
    <time_frame>10-14 months</time_frame>
    <description>Simple and complex Attention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Conners Continuous Performance Test 3rd Edition</measure>
    <time_frame>10-14 months</time_frame>
    <description>Sustained Attention and Behavioral Inhibition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Examination of Optical Coherence Tomography</measure>
    <time_frame>10-14 months</time_frame>
    <description>Eye examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Mobility score</measure>
    <time_frame>10-14 months</time_frame>
    <description>Patient Reported Outcomes Measures: Mobility, walking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Pain score</measure>
    <time_frame>10-14 months</time_frame>
    <description>Patient Reported Outcomes Measures: overall pain level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Peer relationship score</measure>
    <time_frame>10-14 months</time_frame>
    <description>Patient Reported Outcomes Measures: Peer relationships</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Stress score</measure>
    <time_frame>10-14 months</time_frame>
    <description>Patient Reported Outcomes Measures: Psychological stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Upper extremity movement score</measure>
    <time_frame>10-14 months</time_frame>
    <description>Patient Reported Outcomes Measures: Upper extremity movement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score of 25 foot timed walk</measure>
    <time_frame>10-14 months</time_frame>
    <description>Walking speed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score of 6 minute timed walk</measure>
    <time_frame>10-14 months</time_frame>
    <description>Walking Distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score of Hauser Ambulation Index</measure>
    <time_frame>10-14 months</time_frame>
    <description>Functional walking assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score of Multiple Sclerosis Functional Capacity (MSFC)</measure>
    <time_frame>10-14 months</time_frame>
    <description>Hand and Eye coordination, Memory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score of Modified Rankin Scale</measure>
    <time_frame>10-14 months</time_frame>
    <description>Disability scale</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <condition>Neuromyelitis Optica</condition>
  <condition>Acute Disseminated Encephalomyelitis</condition>
  <condition>Transverse Myelitis</condition>
  <arm_group>
    <arm_group_label>CNS demyelinating diagnosis</arm_group_label>
    <description>Diagnosis of CNS demyelinating disorder: Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, anti-MOG antibody.
3T and 7T MRI
Neuropsychological testing
Optical Coherence Tomography
Questionnaires: Quality of Life and Behavior scales
Non invasive clinical assessment : Walking, hand and eye coordination tests Repeat same research activities one year later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>3T and 7T MRI
Neuropsychological testing
Optical Coherence Tomography
Questionnaires: Quality of Life and Behavior scales
Non invasive clinical assessment : Walking, hand and eye coordination tests Repeat same research activities one year later</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Teenagers before 18 at the time of consent diagnosis with a Central Nervous System
        demyelinating disorder.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Multiple Sclerosis , ADEM, anti-MOG antibody associated CNS demyelination

          2. Age 12 to 18 inclusive at time of enrollment

          3. Ability of parent or legal guardian to provide informed consent if participant is
             under 18.

          4. Ability of patients age 12 and older to give assent

          5. Completion of the signed HIPPA authorization form by a parent or legal guardian or by
             participants (18 years of age).

        Exclusion Criteria:

          1. Known history of traumatic brain injury that required medical care

          2. Non-English speaking (based on standardized neuropsychological testing and
             questionnaires)

          3. Claustrophobic, pregnant, the presence of metallic braces, implants or medical devices
             that are unsafe at 3T or 7T and/or interfere with the MRI/MRS signals
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Greenberg, MD. MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Texas Southwestern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tricia Plumb, RN, MSN</last_name>
    <phone>214-456-2464</phone>
    <email>patricia.plumb@utsouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tricia Plumb, RN, MSN</last_name>
      <phone>214-456-2464</phone>
      <email>patricia.plumb@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin Greenberg, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lana Harder, PhD, ABPP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin Greenberg</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>NMO</keyword>
  <keyword>anti-MOG</keyword>
  <keyword>Acute Disseminated Encephalolmyelitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelitis, Transverse</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuromyelitis Optica</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Encephalomyelitis</mesh_term>
    <mesh_term>Myelitis</mesh_term>
    <mesh_term>Encephalomyelitis, Acute Disseminated</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

